The European Medicines Agency (EMA) approved mavacamten in June 2023 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).1,2 Clinical trials have demonstrated its efficacy in improving exercise capacity, reducing the left ventricular outflow tract (LVOT) gradient, and alleviating symptoms, and decreases the need for invasive septal reduction therapies.3,4
Pharmacogenetic testing to broaden patient eligibility for mavacamten / Van der Linden, Lorenz; Van Aelst, Lucas; Olivotto, Iacopo. - In: EUROPEAN HEART JOURNAL. CARDIOVASCULAR PHARMACOTHERAPY. - ISSN 2055-6837. - ELETTRONICO. - (2024), pp. 0-0. [10.1093/ehjcvp/pvae086]
Pharmacogenetic testing to broaden patient eligibility for mavacamten
Olivotto, Iacopo
2024
Abstract
The European Medicines Agency (EMA) approved mavacamten in June 2023 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).1,2 Clinical trials have demonstrated its efficacy in improving exercise capacity, reducing the left ventricular outflow tract (LVOT) gradient, and alleviating symptoms, and decreases the need for invasive septal reduction therapies.3,4
| File | Dimensione | Formato | |
|---|---|---|---|
|
pvae086.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
267.06 kB
Formato
Adobe PDF
|
267.06 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
